| Moderator 主持人 | Runlin Gao 高润霖, Yaling Han 韩雅玲 | |
| Discussant 讨论者 | Guosheng Fu 傅国胜, Jinghua Liu 柳景华, Yu Wang 王禹, Zuyi Yuan 袁祖贻, Jinqing Yuan 袁晋青 | |
|
8:00 AM- |
Opening Remarks 开场致辞 |
Runlin Gao 高润霖 |
|
8:05 AM- |
The GPI Era, Bivalirudin Compare with UFH+GPI CAN Get More Benefits for ACS Patients Undergoing PCI 在GPI时代，拟行PCI的ACS病人中，比伐芦定与肝素联合GPI相比能带来更多临床获益 |
Jie Qian 钱杰 |
|
8:25 AM- |
Post GPI Era, If Bivalirudin Still Get Benefits? Bivalirudin Compare with UFH Monotherapy STILL Get More Benefits for High Bleeding Risk Patients Undergoing PCI 后GPI时代，比伐芦定是否仍能带来获益？在拟行PCI的高危出血风险病人中，比伐芦定与肝素单药相比仍能带来获益 |
Xiantao Song 宋现涛 |
|
8:45 AM- |
Panel Discussion with Audience Q&A 专家讨论及听众问答 |
|
|
8:55 AM- |
If Different P2Y12 Inhibitors with Bivalirudin Anticoagulation Can Get Benefits? - Clopidogrel with Bivalirudin Anticoagulation Peri-PCI Can Get Benefits 术前不同的P2Y12，术中比伐芦定抗凝是否都能带来获益？- 比伐芦定联合氯吡格雷能带来获益 |
Fei Ye 叶飞 |
|
9:15 AM- |
If Different P2Y12 Inhibitors with Bivalirudin Anticoagulation Can Get Benefits? - Potent P2Y12 Inhibitors with Bivalirudin Anticoagulation Peri-PCI Still Get Benefits 术前不同的P2Y12，术中比伐芦定抗凝是否都能带来获益？- 比伐芦定联合强效P2Y12仍能带来获益 |
Kai Xu 徐凯 |
|
9:35 AM- |
Panel Discussion with Audience Q&A 专家讨论及听众问答 |
|
|
9:40 AM- |
Summary 总结 |
Yaling Han 韩雅玲 |
|
9:45 AM- |
Adjourn 休会 |
|